EVALUATION OF ANTIVIRALS FOR HEPATITIS C VIRUS IN CHIMPANZEES

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 研究中心，而研究中心不一定是研究者所在的机构。 大约2%的美国人口是慢性感染丙型肝炎病毒（HCV）。 慢性HCV感染导致严重的肝脏疾病，包括肝硬化和肝癌，约20%的感染者。 目前的干扰素和利巴韦林治疗在大多数情况下不能清除病毒。 开发改进的抗病毒策略来治疗HCV慢性感染对于控制这种疾病至关重要。 本研究的目的是在慢性感染的黑猩猩中测试一系列核苷类似物作为HCV复制的抗病毒抑制剂。 通过TaqMan RT-PCR测量血清中病毒RNA的水平，并监测动物的化合物安全性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Approximately 2% of the US population is chronically infected with hepatitis C virus (HCV). Chronic HCV infections result in significant liver disease, including cirrhosis and liver cancer in approximately 20% of infected individuals. The current therapy of interferon and ribavirin does not result in viral clearance in the majority of cases. The development of improved antiviral strategies to treat HCV chronic infection is essential for the control of this disease. The objective of this study is to test a series of nucleoside analogues as antiviral inhibitors of HCV replication in chronically infected chimpanzees. The level of viral RNA in the serum is being measured by TaqMan RT-PCR, and the animals are being monitored for safety of the compounds.